Pub Date : 2024-05-03DOI: 10.1097/js9.0000000000001521
Yongguang Liu, Runtao Feng, Jianrong Chen, Hongyan Yan, Xiaoyou Liu
{"title":"Optimizing post-transplantation outcomes: the role of multi-omics, artificial intelligence, and animal models in addressing immunosuppression-associated hepatotoxicity","authors":"Yongguang Liu, Runtao Feng, Jianrong Chen, Hongyan Yan, Xiaoyou Liu","doi":"10.1097/js9.0000000000001521","DOIUrl":"https://doi.org/10.1097/js9.0000000000001521","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"95 S4","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141017616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03DOI: 10.1097/js9.0000000000001546
J. Meng, Yilan Yang, Jiaojie Lv, Hong Lv, Xu Zhao, Li Zhang, Wei Shi, Zhaozhi Yang, X. Mei, Xing-Xing Chen, Jinli Ma, Zhen Zhang, Zhimin Shao, Xiaoli Yu, Xiaomao Guo
The chemokine receptor CXCR6 is critical for sustained tumor control mediated by CD8+ cytotoxic T cells (CTLs) in tumors. Previous studies have shown that ionizing radiation induces an inflamed immune contexture by upregulating CXCR6. However, the clinical significance of CXCR6 expression in triple-negative breast cancer (TNBC) and its correlation with radiotherapy remains unknown. This study aimed to clarify the prognostic value of CXCR6 and its role in the breast tumor microenvironment (TME). The mRNA and protein expression of CXCR6 in human triple-negative breast cancer and their association with survival were analyzed. The role of CXCR6 in the immune context was investigated using a combination of single-cell RNA sequencing, general transcriptome sequencing data and fluorescence-based multiplex immunohistochemistry (mIHC) techniques. Elevated CXCR6 expression correlated with better clinical outcomes and superior response to adjuvant radiotherapy and immunotherapy in TNBC. CXCR6 fostered an immunostimulatory microenvironment characterized by upregulated cytotoxic markers. We also found that CXCR6 plays a crucial role in regulating the differentiation of CD8+ T cells and the intercellular communication of immune cell subtypes, shaping the anti-tumor microenvironment. This study highlights the emerging role of CXCR6 in shaping the antitumor immune microenvironment, and targeting CXCR6 may be a promising strategy for improving the effectiveness of radiotherapy and immunotherapy in TNBC.
趋化因子受体 CXCR6 对于肿瘤中 CD8+ 细胞毒性 T 细胞（CTL）介导的持续肿瘤控制至关重要。以往的研究表明，电离辐射会通过上调 CXCR6 来诱导炎症免疫环境。然而，CXCR6表达在三阴性乳腺癌（TNBC）中的临床意义及其与放疗的相关性仍然未知。本研究旨在阐明CXCR6的预后价值及其在乳腺肿瘤微环境（TME）中的作用。 研究分析了CXCR6在人类三阴性乳腺癌中的mRNA和蛋白表达及其与生存的关系。研究结合单细胞RNA测序、通用转录组测序数据和基于荧光的多重免疫组化（mIHC）技术，探讨了CXCR6在免疫环境中的作用。 CXCR6表达的升高与TNBC更好的临床疗效以及对辅助放疗和免疫疗法的良好反应相关。CXCR6促进了以细胞毒性标志物上调为特征的免疫刺激微环境。我们还发现，CXCR6 在调控 CD8+ T 细胞分化和免疫细胞亚型的细胞间交流、塑造抗肿瘤微环境方面发挥着至关重要的作用。 这项研究强调了CXCR6在塑造抗肿瘤免疫微环境中的新作用，靶向CXCR6可能是提高TNBC放疗和免疫治疗效果的一种有前途的策略。
{"title":"CXCR6 expression correlates with radiotherapy response and immune context in triple-negative breast cancer (Experimental Studies)","authors":"J. Meng, Yilan Yang, Jiaojie Lv, Hong Lv, Xu Zhao, Li Zhang, Wei Shi, Zhaozhi Yang, X. Mei, Xing-Xing Chen, Jinli Ma, Zhen Zhang, Zhimin Shao, Xiaoli Yu, Xiaomao Guo","doi":"10.1097/js9.0000000000001546","DOIUrl":"https://doi.org/10.1097/js9.0000000000001546","url":null,"abstract":"\u0000 \u0000 The chemokine receptor CXCR6 is critical for sustained tumor control mediated by CD8+ cytotoxic T cells (CTLs) in tumors. Previous studies have shown that ionizing radiation induces an inflamed immune contexture by upregulating CXCR6. However, the clinical significance of CXCR6 expression in triple-negative breast cancer (TNBC) and its correlation with radiotherapy remains unknown. This study aimed to clarify the prognostic value of CXCR6 and its role in the breast tumor microenvironment (TME).\u0000 \u0000 \u0000 \u0000 The mRNA and protein expression of CXCR6 in human triple-negative breast cancer and their association with survival were analyzed. The role of CXCR6 in the immune context was investigated using a combination of single-cell RNA sequencing, general transcriptome sequencing data and fluorescence-based multiplex immunohistochemistry (mIHC) techniques.\u0000 \u0000 \u0000 \u0000 Elevated CXCR6 expression correlated with better clinical outcomes and superior response to adjuvant radiotherapy and immunotherapy in TNBC. CXCR6 fostered an immunostimulatory microenvironment characterized by upregulated cytotoxic markers. We also found that CXCR6 plays a crucial role in regulating the differentiation of CD8+ T cells and the intercellular communication of immune cell subtypes, shaping the anti-tumor microenvironment.\u0000 \u0000 \u0000 \u0000 This study highlights the emerging role of CXCR6 in shaping the antitumor immune microenvironment, and targeting CXCR6 may be a promising strategy for improving the effectiveness of radiotherapy and immunotherapy in TNBC.\u0000","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"107 4","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141016176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03DOI: 10.1097/js9.0000000000001496
R. Cahill
{"title":"Cognitive vision- AI automation of the surgical eye in fluorescence angiography. Correspondence","authors":"R. Cahill","doi":"10.1097/js9.0000000000001496","DOIUrl":"https://doi.org/10.1097/js9.0000000000001496","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"17 S20","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141016620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03DOI: 10.1097/js9.0000000000001530
ZuJun Wen
{"title":"Enhancing the understanding of association between breast-conserving surgery with a lower incidence of suicide among females with breast cancer","authors":"ZuJun Wen","doi":"10.1097/js9.0000000000001530","DOIUrl":"https://doi.org/10.1097/js9.0000000000001530","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"150 6","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141015209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03DOI: 10.1097/js9.0000000000001553
Shengke Zhang, Shangke Huang, Guanhu Yang, Hao Chi
{"title":"Letter to editor: Effect of pre-transplant viral therapy on post-transplant hepatitis B virus reactivation in patients with hepatitis B-related hepatocellular carcinoma","authors":"Shengke Zhang, Shangke Huang, Guanhu Yang, Hao Chi","doi":"10.1097/js9.0000000000001553","DOIUrl":"https://doi.org/10.1097/js9.0000000000001553","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"119 23","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141017313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03DOI: 10.1097/js9.0000000000001497
Yuquan Chen, Yanwei You, Qi Zhang, Qiang Cao
{"title":"A commentary on “concerns regarding “metabolic syndrome and surgical complications: A systematic review and meta-analysis of 13 million individuals”","authors":"Yuquan Chen, Yanwei You, Qi Zhang, Qiang Cao","doi":"10.1097/js9.0000000000001497","DOIUrl":"https://doi.org/10.1097/js9.0000000000001497","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"11 5","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141014830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.1158/1538-7445.sabcs23-po2-23-12
Elizabeth Stolarik, Jorryn Zelek, Mariah Thigpen, Anita Davidson, Donald J. Davidson
For many patients with metastatic breast cancer (MBC), their disease is treatable but incurable. Although the rate of death from MBC has significantly decreased over the last 10 years due to early detection and new treatment options, MBC still accounts for over 40,000 deaths each year in the US that has been consistent for the past 30 years. Recently, it is estimated that 90% of those deaths were due to drug resistant recurrent disease. Nearly 45% of MBC deaths can be attributed to a subpopulation of patients with metastatic triple negative breast cancer (mTNBC). Despite MBC’s initial sensitivity to chemotherapy, it often recurs at greater than 40% in stage I-III patients and greater than 80% in stage IV patients which have a dismal 5-year survival of 12%. African American women have a 40% greater incidence of death from MBC despite a 4% lower risk of diagnosis. Unfortunately, current therapies do little to reduce drug resistance and death for recurrent drug resistant MBC. Currently, the only therapies approved by the FDA for recurrent TNBC patients are Keytruda plus chemotherapy and an Antibody Drug Conjugate (ADC) called Sacituzumab Govitecan. Keytruda (anti-PD-L1) is an immune checkpoint inhibitor(ICI) given with chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin). The second recently approved therapy, Sacituzumab Govitecan (SG), is composed of an antibody to human trophoblast cell-surface antigen 2 (Trpo-2) coupled to SN-38 (topoisomerase I inhibitor). Although these results are very encouraging, the 80% of TNBC patients that either do not have high positive PD-L1 tumors, or don’t respond to these therapies and become drug resistant suggests that most patients with TNBC will have recurrent disease with little or no hope for survival. For contrast, our novel MBC therapy, CBT300, targets cell surface GRP78 that has been found in over 95% of MBC and in 93% of TNBC tumors. We can now show that inhibition of cell surface GRP78 can a) induce apoptosis of drug resistant TNBC cells in vitro and in vivo, b) eliminate drug resistance showing synergistic effects with chemotherapy in vitro and in vivo, c) decrease amount of chemotherapy in combination with CBT300 and d) reduce immune suppression. Recent publications show that GRP78 is found on many types of tumor cell surfaces but not on normal cell surfaces. In fact, tumor cell surface GRP78 (csGRP78) is important for many aspects of MBC development, including cell survival, proliferation, chemoresistance, angiogenesis, metastasis formation, immune suppression, and stem cell formation. Recently, it has been shown that increased cell surface GRP78 expression in TNBC patients was significantly associated with later stage, increased distant metastasis, increased aggressiveness, shorter disease-free survival, and decreased overall survival. In studies to help understand how cell surface GRP78 causes MBC progression and drug resistance, we discovered a novel GRP78 binding transmemb
对于许多转移性乳腺癌（MBC）患者来说，他们的疾病可以治疗，但却无法治愈。虽然由于早期发现和新的治疗方案，MBC 的死亡率在过去 10 年中大幅下降，但在过去 30 年中，美国每年仍有超过 40,000 人死于 MBC。最近，据估计这些死亡病例中有 90% 是由于耐药复发所致。近 45% 的 MBC 死亡病例可归因于转移性三阴性乳腺癌（mTNBC）患者亚群。尽管 MBC 最初对化疗敏感，但 I-III 期患者的复发率往往超过 40%，IV 期患者的复发率超过 80%，5 年生存率仅为 12%。尽管非裔美国妇女确诊的风险比男性乳腺癌患者低 4%，但她们死于男性乳腺癌的几率却比后者高出 40%。不幸的是，目前的疗法在减少耐药性和复发性耐药性 MBC 的死亡方面收效甚微。目前，FDA 批准用于复发性 TNBC 患者的疗法只有 Keytruda 加化疗和一种名为 Sacituzumab Govitecan 的抗体药物共轭物 (ADC)。Keytruda（抗-PD-L1）是一种免疫检查点抑制剂（ICI），与化疗（纳布紫杉醇、紫杉醇或吉西他滨加卡铂）一起使用。最近获批的第二种疗法萨妥珠单抗戈维替康（SG）由人滋养层细胞表面抗原2（Trpo-2）抗体和SN-38（拓扑异构酶I抑制剂）组成。尽管这些结果非常令人鼓舞，但80%的TNBC患者要么没有PD-L1高阳性肿瘤，要么对这些疗法没有反应并产生耐药性，这表明大多数TNBC患者的病情会反复发作，生存希望渺茫或根本没有希望。相比之下，我们的新型 MBC 疗法 CBT300 以细胞表面 GRP78 为靶点，在 95% 以上的 MBC 和 93% 的 TNBC 肿瘤中都发现了 GRP78。我们现在可以证明，抑制细胞表面 GRP78 可以：a）在体外和体内诱导耐药 TNBC 细胞凋亡；b）消除耐药性，在体外和体内与化疗产生协同效应；c）减少与 CBT300 联合使用时的化疗量；d）减少免疫抑制。最近的出版物显示，GRP78 存在于多种类型的肿瘤细胞表面，但不存在于正常细胞表面。事实上，肿瘤细胞表面的 GRP78（csGRP78）对 MBC 的许多方面的发展都很重要，包括细胞存活、增殖、化疗抵抗、血管生成、转移形成、免疫抑制和干细胞形成。最近的研究表明，TNBC 患者细胞表面 GRP78 表达的增加与晚期、远处转移增加、侵袭性增加、无病生存期缩短和总生存期降低显著相关。为帮助了解细胞表面 GRP78 如何导致 MBC 进展和耐药性，我们在研究中发现了 TNBC 细胞中一种新型 GRP78 结合跨膜蛋白，名为受体酪氨酸激酶孤儿受体-1（ROR1）。利用 ROR1 的 GRP78 结合结构域和人类 Fc IgG1 结构域，我们创造出了一种生物融合蛋白--CBT300，它是一种强效的细胞表面特异性 GRP78 抑制剂。我们现在证明，CBT300 消除细胞表面 GRP78 的作用能破坏肿瘤细胞表面 ROR1、Cripto-1 和检查点蛋白 PD-L1 的稳定性并将其从肿瘤细胞表面清除，从而逆转化疗抗性、减少免疫抑制、抑制干细胞表型并增加肿瘤细胞凋亡。由于ROR1、Cripto-1和PD-L1是肿瘤耐药、免疫抑制和干细胞形成的三个主要冗余通路，因此用CBT300这种安全、高效的单一疗法来抑制所有这些通路是非常创新的，可能是治疗MBC的一个重大进展。引用格式：Elizabeth Stolarik, Jorryn Zelek, Mariah Thigpen, Anita Davidson, Donald Davidson.创新性转移性乳腺癌疗法 CBT300 可逆转药物和免疫抗药性 [摘要]。In：2023 年圣安东尼奥乳腺癌研讨会论文集；2023 年 12 月 5-9 日；德克萨斯州圣安东尼奥。费城（宾夕法尼亚州）：AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-23-12.
{"title":"Abstract PO2-23-12: Innovative Metastatic Breast Cancer Therapy, CBT300, Reverses Drug and Immune Resistance","authors":"Elizabeth Stolarik, Jorryn Zelek, Mariah Thigpen, Anita Davidson, Donald J. Davidson","doi":"10.1158/1538-7445.sabcs23-po2-23-12","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs23-po2-23-12","url":null,"abstract":"\u0000 For many patients with metastatic breast cancer (MBC), their disease is treatable but incurable. Although the rate of death from MBC has significantly decreased over the last 10 years due to early detection and new treatment options, MBC still accounts for over 40,000 deaths each year in the US that has been consistent for the past 30 years. Recently, it is estimated that 90% of those deaths were due to drug resistant recurrent disease. Nearly 45% of MBC deaths can be attributed to a subpopulation of patients with metastatic triple negative breast cancer (mTNBC). Despite MBC’s initial sensitivity to chemotherapy, it often recurs at greater than 40% in stage I-III patients and greater than 80% in stage IV patients which have a dismal 5-year survival of 12%. African American women have a 40% greater incidence of death from MBC despite a 4% lower risk of diagnosis. Unfortunately, current therapies do little to reduce drug resistance and death for recurrent drug resistant MBC.\u0000 Currently, the only therapies approved by the FDA for recurrent TNBC patients are Keytruda plus chemotherapy and an Antibody Drug Conjugate (ADC) called Sacituzumab Govitecan. Keytruda (anti-PD-L1) is an immune checkpoint inhibitor(ICI) given with chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin). The second recently approved therapy, Sacituzumab Govitecan (SG), is composed of an antibody to human trophoblast cell-surface antigen 2 (Trpo-2) coupled to SN-38 (topoisomerase I inhibitor). Although these results are very encouraging, the 80% of TNBC patients that either do not have high positive PD-L1 tumors, or don’t respond to these therapies and become drug resistant suggests that most patients with TNBC will have recurrent disease with little or no hope for survival.\u0000 For contrast, our novel MBC therapy, CBT300, targets cell surface GRP78 that has been found in over 95% of MBC and in 93% of TNBC tumors. We can now show that inhibition of cell surface GRP78 can a) induce apoptosis of drug resistant TNBC cells in vitro and in vivo, b) eliminate drug resistance showing synergistic effects with chemotherapy in vitro and in vivo, c) decrease amount of chemotherapy in combination with CBT300 and d) reduce immune suppression. Recent publications show that GRP78 is found on many types of tumor cell surfaces but not on normal cell surfaces. In fact, tumor cell surface GRP78 (csGRP78) is important for many aspects of MBC development, including cell survival, proliferation, chemoresistance, angiogenesis, metastasis formation, immune suppression, and stem cell formation. Recently, it has been shown that increased cell surface GRP78 expression in TNBC patients was significantly associated with later stage, increased distant metastasis, increased aggressiveness, shorter disease-free survival, and decreased overall survival. In studies to help understand how cell surface GRP78 causes MBC progression and drug resistance, we discovered a novel GRP78 binding transmemb","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"77 5","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141021904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.1158/1538-7445.sabcs23-po1-07-08
Alexis Simon, Yasmina Badachi, Jacques Ropers, Isaura Laurent, Lida Dong, Elisabeth Da Maia, Agnès Bourcier, Geoffroy Canlorbe, C. Uzan
BACKGROUND: Full field optical coherence tomography combined to dynamic cell imaging (D-FFOCT) is a new, simple to use, nondestructive, quick technique than can provide sufficient spatial resolution to mimic histopathological analysis. The objective of this study was to evaluate diagnostic performance of D-FFOCT for one-stop rapid diagnosis breast clinic. METHODS: D-FFOCT was applied to fresh untreated breast and nodes biopsies. Four different readers (senior and junior radiologist, surgeon and pathologist) analyzed the samples without knowing final histological diagnosis or ACR classification. The results were compared to conventional processing and staining (Hematoxylin-eosin). RESULTS: A total of 217 biopsies were performed on 152 patients. There were 144 breast biopsies and 61 lymph nodes with 101 infiltrative cancers (49,27%), 99 benign lesions (48,29%), 3 ductal in situ carcinoma (1,46%) and 2 atypias (0,98%). The diagnostic performances results were as follow: sensitivity: 77% [0.7;0.82], specificity: 64% [0.58;0.71], PPV: 74% [0.68;0.78] and NPV: 75% [0.72;0.78]. A large images atlas was created as well as a diagnosis algorithm from the readers experience. CONCLUSION: D-FFOCT provides interesting results defining malignancy on fresh breast and nodes samples. By training with the diagnosis algorithm and the images atlas or by using machine learning, radiologists could obtain even better outcomes allowing quick detection of breast cancer and lymph node involvement. diagnosis algorithm Figure 1 Images in DCI and FFOCT Two infiltrating cancer diagnosed on pathology (A,B). Focusing on cells (C). Normal galactophoric duct (D). Adenofibroma (E) Citation Format: Alexis Simon, Yasmina Badachi, Jacques Ropers, Isaura Laurent, Lida Dong, Elisabeth Da Maia, Agnes Bourcier, Geoffroy Canlorbe, Catherine Uzan. Value of high resolution full field optical coherence tomography and dynamic cell imaging (D-FFOCT) for one-stop rapid diagnosis breast clinic [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-07-08.
{"title":"Abstract PO1-07-08: Value of high resolution full field optical coherence tomography and dynamic cell imaging (D-FFOCT) for one-stop rapid diagnosis breast clinic","authors":"Alexis Simon, Yasmina Badachi, Jacques Ropers, Isaura Laurent, Lida Dong, Elisabeth Da Maia, Agnès Bourcier, Geoffroy Canlorbe, C. Uzan","doi":"10.1158/1538-7445.sabcs23-po1-07-08","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs23-po1-07-08","url":null,"abstract":"\u0000 BACKGROUND: Full field optical coherence tomography combined to dynamic cell imaging (D-FFOCT) is a new, simple to use, nondestructive, quick technique than can provide sufficient spatial resolution to mimic histopathological analysis. The objective of this study was to evaluate diagnostic performance of D-FFOCT for one-stop rapid diagnosis breast clinic. METHODS: D-FFOCT was applied to fresh untreated breast and nodes biopsies. Four different readers (senior and junior radiologist, surgeon and pathologist) analyzed the samples without knowing final histological diagnosis or ACR classification. The results were compared to conventional processing and staining (Hematoxylin-eosin). RESULTS: A total of 217 biopsies were performed on 152 patients. There were 144 breast biopsies and 61 lymph nodes with 101 infiltrative cancers (49,27%), 99 benign lesions (48,29%), 3 ductal in situ carcinoma (1,46%) and 2 atypias (0,98%). The diagnostic performances results were as follow: sensitivity: 77% [0.7;0.82], specificity: 64% [0.58;0.71], PPV: 74% [0.68;0.78] and NPV: 75% [0.72;0.78]. A large images atlas was created as well as a diagnosis algorithm from the readers experience. CONCLUSION: D-FFOCT provides interesting results defining malignancy on fresh breast and nodes samples. By training with the diagnosis algorithm and the images atlas or by using machine learning, radiologists could obtain even better outcomes allowing quick detection of breast cancer and lymph node involvement.\u0000 diagnosis algorithm\u0000 Figure 1 Images in DCI and FFOCT\u0000 Two infiltrating cancer diagnosed on pathology (A,B). Focusing on cells (C). Normal galactophoric duct (D). Adenofibroma (E)\u0000 Citation Format: Alexis Simon, Yasmina Badachi, Jacques Ropers, Isaura Laurent, Lida Dong, Elisabeth Da Maia, Agnes Bourcier, Geoffroy Canlorbe, Catherine Uzan. Value of high resolution full field optical coherence tomography and dynamic cell imaging (D-FFOCT) for one-stop rapid diagnosis breast clinic [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-07-08.","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"62 6","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141022105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.1158/1538-7445.sabcs23-po2-12-11
Husain Alhouz, Arwa Azmeh, Maher S Saifo
Background: The latest recommendations in breast cancer treatment protocols with tamoxifen indicate that it should be used from five to 10 years. It depends mainly on the cumulative dose of the drug in the body. Despite its multiplicity, the various studies conducted on this subject did not reach conclusive results. Objectives: This research aims to study retinopathy associated with hormonal treatment of breast cancer using tamoxifen. Methods: A cross-sectional study was conducted at Al-Mouwasat University Hospital on a sample of 130 eyes according to (G-Power) with a statistical power of 95%. The participants were briefed on the research and consented on the ethical considerations. Then, the patients who entered the study were interrogated, clinically examined, and were asked about their medical history, the time of breast cancer diagnosis along with the details about the treatment protocols they underwent or currently undergoing. The refractive errors were measured with an automatic refractive device, then they were examined on the slit lamp to investigate the refractory media, then the corrected and uncorrected visual acuity were taken. Finally, after ensuring that the inclusion criteria were met and excluding those who fulfil one or more of the exclusion criteria, optical coherence tomography was performed using SD-OCT technique to measure and review the retinal thickness map in circles of 1-3-6 mm, respectively, to notice possible changes on it. Results: We found that the use of tamoxifen irrespective to cumulative dose leads to increase in the macula thickness values in the upper and lower sectors within the 3 mm circle, and to significant decrease in the macula thickness values in the upper and lower sectors within the 6 mm circle, in addition to decrease in nasal sector thickness within the circles of 3 and 6 mm. Conclusion: We conclude that the difference between people treated with tamoxifen and those not treated with it is not limited to the occurrence of crystals deposition in the macular area or the presence of a cavity in the central macula (with or without typical cystic macular edema), but rather to existence of macula thickness differences unrelated to the cumulative dose of the drug, whether by increase or decrease in thickness of the upper, lower and nasal segments. Citation Format: Husain Alhouz, Arwa Azmeh, Maher Saifo. Ocular Toxicity of Tamoxifen in Patients with Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-11.
{"title":"Abstract PO2-12-11: Ocular Toxicity of Tamoxifen in Patients with Breast Cancer","authors":"Husain Alhouz, Arwa Azmeh, Maher S Saifo","doi":"10.1158/1538-7445.sabcs23-po2-12-11","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs23-po2-12-11","url":null,"abstract":"\u0000 Background: The latest recommendations in breast cancer treatment protocols with tamoxifen indicate that it should be used from five to 10 years. It depends mainly on the cumulative dose of the drug in the body. Despite its multiplicity, the various studies conducted on this subject did not reach conclusive results. Objectives: This research aims to study retinopathy associated with hormonal treatment of breast cancer using tamoxifen. Methods: A cross-sectional study was conducted at Al-Mouwasat University Hospital on a sample of 130 eyes according to (G-Power) with a statistical power of 95%. The participants were briefed on the research and consented on the ethical considerations. Then, the patients who entered the study were interrogated, clinically examined, and were asked about their medical history, the time of breast cancer diagnosis along with the details about the treatment protocols they underwent or currently undergoing. The refractive errors were measured with an automatic refractive device, then they were examined on the slit lamp to investigate the refractory media, then the corrected and uncorrected visual acuity were taken. Finally, after ensuring that the inclusion criteria were met and excluding those who fulfil one or more of the exclusion criteria, optical coherence tomography was performed using SD-OCT technique to measure and review the retinal thickness map in circles of 1-3-6 mm, respectively, to notice possible changes on it. Results: We found that the use of tamoxifen irrespective to cumulative dose leads to increase in the macula thickness values in the upper and lower sectors within the 3 mm circle, and to significant decrease in the macula thickness values in the upper and lower sectors within the 6 mm circle, in addition to decrease in nasal sector thickness within the circles of 3 and 6 mm. Conclusion: We conclude that the difference between people treated with tamoxifen and those not treated with it is not limited to the occurrence of crystals deposition in the macular area or the presence of a cavity in the central macula (with or without typical cystic macular edema), but rather to existence of macula thickness differences unrelated to the cumulative dose of the drug, whether by increase or decrease in thickness of the upper, lower and nasal segments.\u0000 Citation Format: Husain Alhouz, Arwa Azmeh, Maher Saifo. Ocular Toxicity of Tamoxifen in Patients with Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-11.","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"14 5","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141022154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.1158/1538-7445.sabcs23-po2-12-05
Carlos Paiva, Fabiola Dias, Angelo Matthes, Bianca Paiva, C. Souza, D. Lacerda, Augusto Antoniazzi, Maria Fernanda Machado, Matheus Godinho, Crislaine de Lima, Cristiane Cárcano, Marina Zorzetto
Introduction: Chemotherapy-induced alopecia (CIA) is a distressing side effect of breast cancer (BC) treatment. Scalp cooling (SC) devices have shown promise in reducing the severity of CIA. However, the impact of reducing alopecia occurrence on the quality of life of Brazilian patients remains unclear. Objectives: This study aimed to assess the effectiveness of the Capelli System, a new SC device, in reducing CIA. Methods: This was a single-center, controlled, randomized phase 2 clinical trial involving women with TNM stage I to III BC undergoing neoadjuvant or adjuvant doxorubicin-based chemotherapy (AC regimen: doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m², i.v., q21 days), with or without a taxane (paclitaxel or docetaxel). Participants were randomized in a 1:3 ratio into the scalp cooling (n = 33) or control (n = 12) groups. All participants were advised to cut their hair short and avoid heat-inducing tools or processes throughout chemotherapy, using cold or lukewarm water and wide-toothed combs for hair washing. The primary efficacy endpoint was grade 2 alopecia (>50% hair loss or hair shaving due to alopecia) after 4 cycles of AC. Secondary endpoints included measures of hair loss distress (BRHL) and body image (BRBI) from the EORTC Quality of Life Questionnaire - Breast Cancer Module (EORTC QLQ-BR23), as well as symptoms of anxiety and depression from the Hospital Anxiety and Depression Scale (HADS). Fitzpatrick phototype and hair type were assessed. Statistical analyses utilized generalized linear models and Fisher's Exact test (p-value < 0.05). Results: Patients were enrolled from October 11, 2019, to January 17, 2022. Out of the 45 patients included, 8 were excluded: 2 due to intolerance, 1 with alopecia associated with COVID-19, and 5 who withdrew consent (2 with grade 2 headache, 3 without justification). The median age was 44.6 (min-max: 23-63) years, with 18 (40%) and 27 (60%) receiving adjuvant and neoadjuvant chemotherapy, respectively. Grade 2 alopecia or hair shaving occurred in 52% of scalp cooling patients and 100% of controls (p = 0.003), demonstrating a significant 48% reduction in alopecia. There were no significant differences in HADS-A, HADS-D, BRHL, or BRBI scores between the two groups. Alopecia occurrence did not show significant associations with skin or hair types. No serious adverse events related to the scalp cooling device were reported. Conclusions: SC with the Capelli System significantly reduced CIA by half. Some patients experienced discomfort or headaches and discontinued device use. Further research is needed to understand why reduced alopecia rates do not correlate with improvements in body image or reduced hair loss distress. Citation Format: Carlos Paiva, Fabiola Dias, Angelo Matthes, Bianca Paiva, Cristiano Souza, Domício Lacerda, Augusto Antoniazzi, Maria Fernanda Machado, Matheus Godinho, Crislaine de Lima, Cristiane Cárcano, Marina Zorzetto. Scalp Cooling with the Capelli System to Redu
简介化疗引起的脱发（CIA）是乳腺癌（BC）治疗过程中令人痛苦的副作用。头皮冷却（SC）设备有望减轻化疗引起的脱发的严重程度。然而，减少脱发对巴西患者生活质量的影响仍不清楚。研究目的本研究旨在评估新型头皮冷却设备 Capelli 系统在减轻 CIA 方面的效果。方法：这是一项单中心对照研究：这是一项单中心、对照、随机的二期临床试验，涉及接受以多柔比星为基础的新辅助化疗或辅助化疗（AC 方案：多柔比星 60 毫克/平方米加环磷酰胺 600 毫克/平方米，静脉注射，q21 天）的 TNM I 期至 III 期 BC 女性患者，无论是否使用类固醇类药物（紫杉醇或多西他赛）。参与者按 1:3 的比例随机分为头皮冷却组（33 人）或对照组（12 人）。所有参与者都被建议剪短头发，在整个化疗过程中避免使用发热工具或过程，使用冷水或温水以及宽齿梳子洗头。主要疗效终点是接受 4 个周期 AC 后的 2 级脱发（脱发率大于 50%，或因脱发而剃发）。次要终点包括EORTC生活质量问卷--乳腺癌模块（EORTC QLQ-BR23）中的脱发困扰（BRHL）和身体形象（BRBI）测量指标，以及医院焦虑抑郁量表（HADS）中的焦虑和抑郁症状。还对 Fitzpatrick 光型和毛发类型进行了评估。统计分析采用了广义线性模型和费雪精确检验（p 值小于 0.05）。结果患者入组时间为 2019 年 10 月 11 日至 2022 年 1 月 17 日。在纳入的 45 名患者中，有 8 人被排除在外：2例因不耐受，1例因与COVID-19相关的脱发，5例撤回同意（2例因2级头痛，3例无正当理由）。中位年龄为 44.6 岁（最小-最大：23-63 岁），分别有 18 人（40%）和 27 人（60%）接受了辅助化疗和新辅助化疗。52%的头皮冷却患者和100%的对照组患者出现了2级脱发或剃发（P = 0.003），表明脱发率显著降低了48%。两组患者的 HADS-A、HADS-D、BRHL 或 BRBI 评分无明显差异。脱发的发生与皮肤或毛发类型没有明显关联。没有与头皮冷却装置相关的严重不良事件报告。结论使用卡佩利系统进行头皮冷却后，CIA明显减少了一半。一些患者感到不适或头痛，因此停止了设备的使用。需要进一步研究，以了解为什么脱发率的降低与身体形象的改善或脱发困扰的减少无关。引用格式：Carlos Paiva, Fabiola Dias, Angelo Matthes, Bianca Paiva, Cristiano Souza, Domício Lacerda, Augusto Antoniazzi, Maria Fernanda Machado, Matheus Godinho, Crislaine de Lima, Cristiane Cárcano, Marina Zorzetto.使用卡佩利系统进行头皮冷却以减少局部乳腺癌患者由多柔比星引起的脱发：2期随机对照试验[摘要]。In：2023 年圣安东尼奥乳腺癌研讨会论文集；2023 年 12 月 5-9 日；德克萨斯州圣安东尼奥。费城（宾夕法尼亚州）：AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-05.
{"title":"Abstract PO2-12-05: Scalp Cooling with the Capelli System to Reduce Doxorubicin-induced Alopecia in Patients with Localized Breast Cancer: A Phase 2 Randomized Controlled Trial","authors":"Carlos Paiva, Fabiola Dias, Angelo Matthes, Bianca Paiva, C. Souza, D. Lacerda, Augusto Antoniazzi, Maria Fernanda Machado, Matheus Godinho, Crislaine de Lima, Cristiane Cárcano, Marina Zorzetto","doi":"10.1158/1538-7445.sabcs23-po2-12-05","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs23-po2-12-05","url":null,"abstract":"\u0000 Introduction: Chemotherapy-induced alopecia (CIA) is a distressing side effect of breast cancer (BC) treatment. Scalp cooling (SC) devices have shown promise in reducing the severity of CIA. However, the impact of reducing alopecia occurrence on the quality of life of Brazilian patients remains unclear.\u0000 Objectives: This study aimed to assess the effectiveness of the Capelli System, a new SC device, in reducing CIA.\u0000 Methods: This was a single-center, controlled, randomized phase 2 clinical trial involving women with TNM stage I to III BC undergoing neoadjuvant or adjuvant doxorubicin-based chemotherapy (AC regimen: doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m², i.v., q21 days), with or without a taxane (paclitaxel or docetaxel). Participants were randomized in a 1:3 ratio into the scalp cooling (n = 33) or control (n = 12) groups. All participants were advised to cut their hair short and avoid heat-inducing tools or processes throughout chemotherapy, using cold or lukewarm water and wide-toothed combs for hair washing. The primary efficacy endpoint was grade 2 alopecia (>50% hair loss or hair shaving due to alopecia) after 4 cycles of AC. Secondary endpoints included measures of hair loss distress (BRHL) and body image (BRBI) from the EORTC Quality of Life Questionnaire - Breast Cancer Module (EORTC QLQ-BR23), as well as symptoms of anxiety and depression from the Hospital Anxiety and Depression Scale (HADS). Fitzpatrick phototype and hair type were assessed. Statistical analyses utilized generalized linear models and Fisher's Exact test (p-value < 0.05).\u0000 Results: Patients were enrolled from October 11, 2019, to January 17, 2022. Out of the 45 patients included, 8 were excluded: 2 due to intolerance, 1 with alopecia associated with COVID-19, and 5 who withdrew consent (2 with grade 2 headache, 3 without justification). The median age was 44.6 (min-max: 23-63) years, with 18 (40%) and 27 (60%) receiving adjuvant and neoadjuvant chemotherapy, respectively. Grade 2 alopecia or hair shaving occurred in 52% of scalp cooling patients and 100% of controls (p = 0.003), demonstrating a significant 48% reduction in alopecia. There were no significant differences in HADS-A, HADS-D, BRHL, or BRBI scores between the two groups. Alopecia occurrence did not show significant associations with skin or hair types. No serious adverse events related to the scalp cooling device were reported.\u0000 Conclusions: SC with the Capelli System significantly reduced CIA by half. Some patients experienced discomfort or headaches and discontinued device use. Further research is needed to understand why reduced alopecia rates do not correlate with improvements in body image or reduced hair loss distress.\u0000 Citation Format: Carlos Paiva, Fabiola Dias, Angelo Matthes, Bianca Paiva, Cristiano Souza, Domício Lacerda, Augusto Antoniazzi, Maria Fernanda Machado, Matheus Godinho, Crislaine de Lima, Cristiane Cárcano, Marina Zorzetto. Scalp Cooling with the Capelli System to Redu","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"61 2","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141022245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：